Taiwanese (TAIEX) Biotech Industry Analysis
UpdatedMay 19, 2024
DataAggregated Company Financials
Companies61
- 7D7.4%
- 3M2.7%
- 1Y-8.4%
- YTD0.3%
Over the last 7 days, the Biotech industry has risen 7.4%, driven by gains from PharmaEssentia of 31%. In the same time, Tanvex BioPharma was down 10%. However, the industry is down 8.4% over the past year. Looking forward, earnings are forecast to grow by 68% annually.
Industry Valuation and Performance
Has the Taiwanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 19 May 2024 | NT$489.9b | NT$21.7b | -NT$11,004,689,000.00 | 43.2x | -44.5x | 22.5x |
| Tue, 16 Apr 2024 | NT$448.0b | NT$20.8b | -NT$12,061,940,000.00 | 49.2x | -37.1x | 21.5x |
| Thu, 14 Mar 2024 | NT$437.4b | NT$20.8b | -NT$9,912,839,000.00 | 42.9x | -44.1x | 21.1x |
| Sat, 10 Feb 2024 | NT$436.3b | NT$19.9b | -NT$9,857,794,000.00 | 40.5x | -44.3x | 21.9x |
| Mon, 08 Jan 2024 | NT$471.0b | NT$19.8b | -NT$9,748,146,000.00 | 39.3x | -48.3x | 23.8x |
| Wed, 06 Dec 2023 | NT$490.9b | NT$19.9b | -NT$9,737,975,000.00 | 43.1x | -50.4x | 24.7x |
| Fri, 03 Nov 2023 | NT$466.3b | NT$18.4b | -NT$10,823,013,000.00 | 49.9x | -43.1x | 25.3x |
| Sun, 01 Oct 2023 | NT$477.3b | NT$18.3b | -NT$10,774,226,000.00 | 43.3x | -44.3x | 26.1x |
| Tue, 29 Aug 2023 | NT$478.4b | NT$18.3b | -NT$10,598,878,000.00 | 41.6x | -45.1x | 26.1x |
| Thu, 27 Jul 2023 | NT$470.7b | NT$18.7b | -NT$10,724,655,000.00 | 44x | -43.9x | 25.2x |
| Sat, 24 Jun 2023 | NT$470.5b | NT$18.7b | -NT$10,709,428,000.00 | 42.6x | -43.9x | 25.2x |
| Mon, 22 May 2023 | NT$478.9b | NT$19.3b | -NT$9,957,876,000.00 | 42.5x | -48.1x | 24.9x |
| Wed, 19 Apr 2023 | NT$516.5b | NT$18.5b | -NT$9,609,324,000.00 | 42.7x | -53.8x | 27.9x |
| Fri, 17 Mar 2023 | NT$485.1b | NT$22.3b | -NT$7,407,579,000.00 | 36.6x | -65.5x | 21.8x |
| Sun, 12 Feb 2023 | NT$532.0b | NT$21.8b | -NT$7,832,470,000.00 | 38x | -67.9x | 24.4x |
| Tue, 10 Jan 2023 | NT$496.3b | NT$21.8b | -NT$7,778,690,000.00 | 36.2x | -63.8x | 22.8x |
| Thu, 08 Dec 2022 | NT$524.9b | NT$21.8b | -NT$7,522,211,000.00 | 38.6x | -69.8x | 24.1x |
| Sat, 05 Nov 2022 | NT$468.2b | NT$23.1b | -NT$6,633,590,000.00 | 37.4x | -70.6x | 20.3x |
| Mon, 03 Oct 2022 | NT$515.6b | NT$23.1b | -NT$6,633,590,000.00 | 37.4x | -77.7x | 22.3x |
| Wed, 31 Aug 2022 | NT$622.6b | NT$23.0b | -NT$6,443,294,000.00 | 41.9x | -96.6x | 27.1x |
| Fri, 29 Jul 2022 | NT$558.9b | NT$22.5b | -NT$5,642,821,000.00 | 31.5x | -99x | 24.8x |
| Sun, 26 Jun 2022 | NT$530.6b | NT$22.5b | -NT$5,642,821,000.00 | 32x | -94x | 23.5x |
| Tue, 24 May 2022 | NT$502.6b | NT$22.5b | -NT$5,642,821,000.00 | 31.7x | -89.1x | 22.3x |
| Thu, 21 Apr 2022 | NT$546.1b | NT$21.5b | -NT$5,726,696,000.00 | 34.8x | -95.4x | 25.5x |
| Sat, 19 Mar 2022 | NT$504.9b | NT$20.0b | -NT$4,463,544,000.00 | 26.7x | -113.1x | 25.2x |
| Mon, 14 Feb 2022 | NT$446.6b | NT$17.9b | -NT$5,532,702,000.00 | 26x | -80.7x | 25x |
| Wed, 12 Jan 2022 | NT$445.4b | NT$17.9b | -NT$5,532,702,000.00 | 26.1x | -80.5x | 24.9x |
| Fri, 10 Dec 2021 | NT$443.2b | NT$17.9b | -NT$5,579,296,000.00 | 23x | -79.4x | 24.7x |
| Sun, 07 Nov 2021 | NT$357.3b | NT$15.4b | -NT$7,624,179,000.00 | 21.1x | -46.9x | 23.2x |
| Tue, 05 Oct 2021 | NT$353.0b | NT$15.4b | -NT$7,624,179,000.00 | 20.6x | -46.3x | 23x |
| Thu, 02 Sep 2021 | NT$384.1b | NT$15.4b | -NT$7,624,179,000.00 | 20.5x | -50.4x | 25x |
| Sat, 31 Jul 2021 | NT$394.2b | NT$15.4b | -NT$7,624,179,000.00 | 21.6x | -51.7x | 25.6x |
Price to Earnings Ratio
-48x
Current Industry PE
- Investors are relatively neutral on the Taiwanese Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 24.3x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 17% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | 2.50% | |
| Healthcare | 3.94% | |
| Biotech | 7.40% | |
| Biotech | 7.40% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6446 PharmaEssentia | NT$408.50 | 30.7% +NT$31.9b | 28.9% | PE306.7x | |
| 6875 Pharmosa Biopharm | NT$75.90 | 9.2% +NT$1.6b | -7.1% | PE1158x | |
| 4162 PharmaEngine | NT$97.90 | 4.9% +NT$660.9m | 4.8% | PE51.2x | |
| 6550 Polaris Group | NT$70.80 | 1.0% +NT$520.4m | -22.9% | PS15030.6x | |
| 6704 Gwo Xi Stem Cell Applied Technology | NT$38.65 | 13.2% +NT$431.8m | -25.4% | PS26.3x |